Disease Stage and Motor Fluctuation Duration Predict Drug Tolerability: A Real-Life, Prospective Italian Multicenter Study on the Use of Opicapone in Parkinson’s Disease-Reference-Cited by-同舟云学术

Disease Stage and Motor Fluctuation Duration Predict Drug Tolerability: A Real-Life, Prospective Italian Multicenter Study on the Use of Opicapone in Parkinson’s Disease

Published:2024-07-02 Issue:3 Volume:11 Page:361-368
ISSN:2199-1154
Container-title:Drugs - Real World Outcomes
language:en
Short-container-title:Drugs - Real World Outcomes

Author:

Bacchin Ruggero^ORCID,Liccari Marco,Catalan Mauro,Antonutti Lucia,Manganotti Paolo,Malaguti Maria Chiara,Giometto Bruno

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40801-024-00442-1.pdf

Reference22 articles.

1. Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–74. https://doi.org/10.1007/s40265-014-0343-0.

2. Rocha JF, Ferreira JJ, Falcão A, et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev. 2016;5(3):232–40. https://doi.org/10.1002/cpdd.217.

3. Ferreira JJ, Rocha JF, Falcão A, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol. 2015;22(5):815–25. https://doi.org/10.1111/ene.12666.

4. Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomized, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154–65. https://doi.org/10.1016/S1474-4422(15)00336-1.

5. Ferreira JJ, Lees AJ, Poewe W, et al. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology. 2018;90(21):1849–57. https://doi.org/10.1212/WNL.0000000000005557.